The promising multiple sclerosis (MS) drug Lemtrada is set to become available to patients throughout the country.
Lemtrada can reduce the effects of the disease and can, in certain cases, enable some recovery.
The National Centre for Pharmacoeconomics (NCPE), which advises the state on whether to fund new drugs, has concluded it represents value for money and is clinically effective.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team